Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430648 · ClinicalTrials.gov registry record
Is Tau Protein Linked to Mobility Function?
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 37
- Enrollment target
NCT03430648: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03430648 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430648 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
This project will provide new data to address an important question linking Alzheimer's disease neuropathology to physical disability.
Primary Outcome
This will be done using the 400m walk test.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2021-09-27 |
What the finished NCT03430648 record still lists
NCT03430648 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03430648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03430648 about?
NCT03430648 is a clinical study titled "Is Tau Protein Linked to Mobility Function?". This project will provide new data to address an important question linking Alzheimer's disease neuropathology to physical disability.
What is the current status of trial NCT03430648?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2017-09-07. Estimated completion is 2021-09-27.
Who is sponsoring clinical trial NCT03430648?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI